These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37501682)

  • 1. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
    Kim BJ; Zheng ZY; Lei JT; Holt MV; Chen A; Peng J; Fandino D; Singh P; Kennedy H; Dou Y; Chica-Parrado MDR; Bikorimana E; Ye D; Wang Y; Hanker AB; Mohamed N; Hilsenbeck SG; Lim B; Asirvatham JR; Sreekumar A; Zhang B; Miles G; Anurag M; Ellis MJ; Chang EC
    Cancer Res Commun; 2023 Jul; 3(7):1366-1377. PubMed ID: 37501682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.
    House RRJ; Tovar EA; Redlon LN; Essenburg CJ; Dischinger PS; Ellis AE; Beddows I; Sheldon RD; Lien EC; Graveel CR; Steensma MR
    Mol Metab; 2024 Feb; 80():101876. PubMed ID: 38216123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer.
    Zheng ZY; Anurag M; Lei JT; Cao J; Singh P; Peng J; Kennedy H; Nguyen NC; Chen Y; Lavere P; Li J; Du XH; Cakar B; Song W; Kim BJ; Shi J; Seker S; Chan DW; Zhao GQ; Chen X; Banks KC; Lanman RB; Shafaee MN; Zhang XH; Vasaikar S; Zhang B; Hilsenbeck SG; Li W; Foulds CE; Ellis MJ; Chang EC
    Cancer Cell; 2020 Mar; 37(3):387-402.e7. PubMed ID: 32142667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
    Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
    BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
    Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
    Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivating
    Pearson A; Proszek P; Pascual J; Fribbens C; Shamsher MK; Kingston B; O'Leary B; Herrera-Abreu MT; Cutts RJ; Garcia-Murillas I; Bye H; Walker BA; Gonzalez De Castro D; Yuan L; Jamal S; Hubank M; Lopez-Knowles E; Schuster EF; Dowsett M; Osin P; Nerurkar A; Parton M; Okines AFC; Johnston SRD; Ring A; Turner NC
    Clin Cancer Res; 2020 Feb; 26(3):608-622. PubMed ID: 31591187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
    Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
    Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Status of
    Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
    Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.
    Gough SM; Flanagan JJ; Teh J; Andreoli M; Rousseau E; Pannone M; Bookbinder M; Willard R; Davenport K; Bortolon E; Cadelina G; Gordon D; Pizzano J; Macaluso J; Soto L; Corradi J; Digianantonio K; Drulyte I; Morgan A; Quinn C; Békés M; Ferraro C; Chen X; Wang G; Dong H; Wang J; Langley DR; Houston J; Gedrich R; Taylor IC
    Clin Cancer Res; 2024 Aug; 30(16):3549-3563. PubMed ID: 38819400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
    Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
    Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
    Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
    Kaminska K; Akrap N; Staaf J; Alves CL; Ehinger A; Ebbesson A; Hedenfalk I; Beumers L; Veerla S; Harbst K; Ehmsen S; Borgquist S; Borg Å; Pérez-Fidalgo A; Ditzel HJ; Bosch A; Honeth G
    Breast Cancer Res; 2021 Feb; 23(1):26. PubMed ID: 33602273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
    Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
    Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ER
    Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
    Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.